Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00140855
Status:
TERMINATED
Last Update Posted:
2022-10-12
First Post:
2005-08-30
Brief Title:
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
Sponsor:
Ludwig Institute for Cancer Research
Organization:
Ludwig Institute for Cancer Research
Study Overview
Official Title:
A Phase II Study of Anti-CTLA-4 Antibody in Advanced Synovial Sarcoma Patients
Status:
TERMINATED
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study discontinued due to poor accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether immune therapy with anti-CTLA-4 antibody is effective in people with advanced synovial sarcoma
Detailed Description:
Approximately 750-900 people in the United States each year develop synovial sarcoma a rare form of cancer of connective tissue This tumor frequently metastasizes to other parts of the body such as the lungs Chemotherapy can sometimes decrease the size of the recurrent tumors but these results are usually only temporary and the tumors grow again
We are trying to exploit some of the proteins made by synovial sarcoma cancer-germ cell or cancer-testis antigens as targets for the immune system Specifically we are investigating if immune-based therapy with anti-CTLA-4 antibody once every 3 weeks for three treatments will activate the immune system enough to attack recurrent synovial sarcoma In this study the tumor itself serves as the vaccine or source of protein as we try to activate tumor-fighting T cells with the anti-CTLA-4
Anti-CTLA-4 takes the brakes off the immune system to allow otherwise hidden immune responses to become more active In so doing there could be other side effects such as immune system attacks against the normal organs of the body We will follow both the anti-tumor immune responses with frequent blood tests and follow and treat side effects people develop on this study to determine if anti-CTLA-4 is worth pursuing in a larger number of patients with synovial sarcoma or other sarcomas
We are trying to exploit some of the proteins made by synovial sarcoma cancer-germ cell or cancer-testis antigens as targets for the immune system Specifically we are investigating if immune-based therapy with anti-CTLA-4 antibody once every 3 weeks for three treatments will activate the immune system enough to attack recurrent synovial sarcoma In this study the tumor itself serves as the vaccine or source of protein as we try to activate tumor-fighting T cells with the anti-CTLA-4
Anti-CTLA-4 takes the brakes off the immune system to allow otherwise hidden immune responses to become more active In so doing there could be other side effects such as immune system attacks against the normal organs of the body We will follow both the anti-tumor immune responses with frequent blood tests and follow and treat side effects people develop on this study to determine if anti-CTLA-4 is worth pursuing in a larger number of patients with synovial sarcoma or other sarcomas
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MSKCC 04-128 | OTHER | MSKCC | None |